Results 31 to 40 of about 23,901 (228)

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. [PDF]

, 2023
UNLABELLED This registry-based study of 3068 patients with osteoporosis compared the anti-fracture effectiveness of denosumab versus bisphosphonates.
Ziswiler, Hans-Rudolf, Gahl, Brigitta, Hans-Rudolf Ziswiler, Harald Bonel, Stephan Reichenbach, Brigitta Gahl, HansJörg Häuselmann, Daniel Lehmann, Judith Everts-Graber, Bonel, Harald, Reichenbach, Stephan, Ueli Studer, Lehmann, Daniel, Thomas Lehmann, Lehmann, Thomas, Studer, Ueli, Everts-Graber, Judith, Häuselmann, HansJörg   +17 more
core   +2 more sources

Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis. [PDF]

, 2018
The aim of the present study was to document the changes in bone mineral density (BMD) 1 year after denosumab loss-of-effect following long-term treatment with subcutaneous denosumab 60 mg Q6M during 7 or 10 years and in the absence of any treatment with
Buffat, Helene, Senn, Christoph, Kurt Lippuner, Helene Buffat, Romain Perrelet, Albrecht Werner Popp, Nadshathra Varathan, Christoph Senn, Popp, Albrecht, Varathan, Nadshathra, Perrelet, Romain, Lippuner, Kurt, Perrelet R, Popp AW, Buffat H, Lippuner K, Senn C, Varathan N   +17 more
core   +2 more sources

Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review [PDF]

Archives of Endocrinology and Metabolism
SUMMARY Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases.
Lisa Schmitt, Verena Theiler-Schwetz, Patrick Sadoghi, Christian Trummer, Stefan Pilz   +4 more
doaj   +1 more source

Denosumab – a new medication in the treatment of postmenopausal osteoporosis

, 2017
Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It leads to an increased risk of bone fractures – one of the major causes of disability in modern societies.
Ewa Milewska, Piotr Rynio, Elżbieta Kubala, Blazej Meczekalski, Radosław Słopień   +4 more
core   +1 more source

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health

Therapeutic Advances in Musculoskeletal Disease
Summary What is this summary about? This plain language summary describes the results of a clinical study, ROSALIA , which was published in the Journal of Bone and Mineral Research in 2024. The ROSALIA study looked at whether biosimilar denosumab has the
Richard Eastell, Sławomir Jeka, Maryam Lustberg, Colin Edgerton, Paweł Żuchowski, Barbara Vogg   +5 more
doaj   +1 more source

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab [PDF]

, 2014
Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal osteoporosis. The therapeutic effect of denosumab rests on its ability to inhibit osteoclast differentiation. Here, we present a computational approach on
Pivonka, P, Smith, D. W., Smith, D, C. Hellmich, P. Pivonka, Hellmich, C., C. R. Dunstan, S. Scheiner, Pivonka, P., Hellmich, C, Scheiner, S., Dunstan, C. R., D. W. Smith, Dunstan, C, Schneiner, S   +14 more
core   +1 more source

Secondary organising pneumonia caused by denosumab [PDF]

, 2023
Introduction: Organising pneumonia belongs to diffuse interstitial lung diseases; we distinguish the cryptogenic organising pneumonia, which is idiopathic, from the secondary organising pneumonia caused by drugs or a defined cause.
Siham Benzait, Bouchra Nesrine Bourouis, Mohammed Amine Banat, Djalaleddine Ouakidi, Abdelmadjid Snouber, Nesrine Azzi   +5 more
core   +1 more source

A Novel Reactive Oxygen Species‐Responsive Bone‐Targeted Nanoplatform Based on Cloperastine Attenuates Ovariectomy‐Induced Bone Loss by Inhibiting Osteoclast Oxidative Phosphorylation

Advanced Science, EarlyView.
Cloperastine suppresses osteoclastogenesis by inhibiting PGC1β‐mediated oxidative phosphorylation. Its incorporation into a ROS‐responsive, Asp8‐modified nanoplatform enhances skeletal accumulation. The resulting Clo/Asp8‐PMK‐MCs combine cloperastine‐mediated antiresorptive activity with carrier‐mediated osteogenic activity to attenuate OVX‐induced ...
Haibo Liang, Yong Xiao, Jiangtao Luo, Xiao Yang, Yayun Yang, Qihang Wu, Chenxin Yu, Zhihao Zhou, Xiaoqing Si, Jiansen Miao, Yiting Tu, Qichen Lu, Boreng Qian, Xiangyang Wang, Jiake Xu, Changcan Shi, Haiming Jin   +16 more
wiley   +1 more source

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

Health Technology Assessment, 2013
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt   +10 more
doaj   +1 more source

DataSheet_1_Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment.docx

, 2021
ObjectivesIn our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment.
Yasuaki Hirooka (11483932), Masafumi Sugiyama (11483935), Masanori Funauchi (9081649), Yuji Nozaki (3165210), Saki Okuda (220166), Itaru Matsumura (332065), Koji Kinoshita (3187932)   +6 more
core   +1 more source